Acura Pharmaceuticals (STU:HD4B) Net Margin %: 81.25% (As of Dec. 2021)


STU:HD4B Acura Pharmaceuticals Inc STU:HD4B
16 GF Score
Price €0.20
View Full Analysis

What is Acura Pharmaceuticals Net Margin %?

Acura Pharmaceuticals STU:HD4B 16 Net Margin % is 81.25% as of Dec. 2021. GuruFocus rates STU:HD4B with a GF Score™ of 16/100.

Net margin is calculated as Net Income divided by its Revenue. Acura Pharmaceuticals's Net Income for the three months ended in Dec. 2021 was €0.03 Mil. Acura Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was €0.03 Mil. Therefore, Acura Pharmaceuticals's net margin for the quarter that ended in Dec. 2021 was 81.25%.

The historical rank and industry rank for Acura Pharmaceuticals's Net Margin % or its related term are showing as below:


STU:HD4B's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.56
* Ranked among companies with meaningful Net Margin % only.

Acura Pharmaceuticals  (STU:HD4B) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Acura Pharmaceuticals Net Margin % Related Terms

Acura Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Acura Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acura Pharmaceuticals Net Margin % Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -191.58 -938.06 -142.07 -33.83 -56.25

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.90 -40.30 -63.06 -96.96 81.25

STU:HD4B vs VFRM, THCT, CBGL: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acura Pharmaceuticals Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Net Margin % falls into.


STU:HD4B
16GF Score
Acura Pharmaceuticals Inc STU:HD4B
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acura Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Acura Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin=Net Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-0.778/1.383
=-56.25 %

Acura Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2021 is calculated as

Net Margin=Net Income (Q: Dec. 2021 )/Revenue (Q: Dec. 2021 )
=0.026/0.032
=81.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 81.25% mean?
Acura Pharmaceuticals (STU:HD4B) has a Net Margin % of 81.25% as of Dec. 2021. Net margin is the ratio of total net income to net sales. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Net Margin % too high?
Acura Pharmaceuticals' current Net Margin % is 81.25%. The Drug Manufacturers industry median Net Margin % is 5.56. Acura Pharmaceuticals' value of 81.25% is 1361.3% above this industry median. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Net Margin % compare to VFRM and THCT?
Acura Pharmaceuticals' Net Margin % of 81.25% can be compared against companies in the Drug Manufacturers industry. The industry median Net Margin % is 5.56. Acura Pharmaceuticals' value of 81.25% is 1361.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acura Pharmaceuticals's current Net Margin % of 81.25% is 1361.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Acura Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acura Pharmaceuticals's current Net Margin % is 81.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Net Margin % of 81.25%. The current Net Margin % is 81.25% and 1361.3% above the Drug Manufacturers industry median of 5.56. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Net Margin % is 81.25% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acura Pharmaceuticals Business Description

Address 616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score

Get the complete analysis for STU:HD4B

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price